Email from Sultan Bin Sulayem to Jeffrey Epstein forwarding Forbes article on FDA‑approved cholesterol drug Praluent

Email from Sultan Bin Sulayem to Jeffrey Epstein forwarding Forbes article on FDA‑approved cholesterol drug Praluent The passage shows a direct communication between a high‑profile Dubai business leader (Sultan Bin Sulayem) and convicted financier Jeffrey Epstein, centered on a newly approved, high‑cost drug. While it does not contain explicit allegations, it suggests a possible conduit for sharing privileged pharmaceutical market information with Epstein, which could imply undisclosed financial or influence relationships. The lead is actionable (identify any related transactions, meetings, or investments) but lacks concrete details on money flows or wrongdoing, keeping the score in the moderate range. Key insights: Sultan Bin Sulayem, head of DP World, emailed Jeffrey Epstein a Forbes article about Praluent.; The email is dated July 24 2015, shortly after FDA approval of the expensive PCSK9 inhibitor.; Praluent’s wholesale cost was projected at $14,600 per year, indicating large revenue potential for Regeneron/Sanofi.